Incidental Findings in Somatostatin Receptor PET (SSTR PET) scans (e.g. Ga68/Cu64)

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 19,512 other subscribers.

Incidental Findings in SSTR PET

Somatostatin Receptor (SSTR) PET scans (e.g. Ga68/Cu64) have transformed the imaging landscape for Neuroendocrine Cancer, mainly for well-differentiated NETs, most of which will be somatostatin receptor positive.  However, Oncologists/NET Specialists and radiologists must be aware of the various physiologic and other pathologic processes in which cellular expression of SSTR can result in interpretative error.  Included in these pitfalls are incidental findings

What is an incidental finding? 

An incidental finding, also known as an incidentaloma, may be defined as “an incidentally discovered mass or lesion, detected by CT, MRI, or other imaging modality (e.g. PET) performed for an unrelated reason.”  An increase in the utilisation of imaging examinations over the past three decades has led to a marked increase in the number of findings detected that are unrelated to the primary objectives of the examinations.

This study cited below covers the prevalence and significance of incidental findings related to Ga68 PET scans (it is likely to be similar to other SSTR PETs).  In fact, this study is a collation of many other studies covering a total of 2906 subjects.  The output is interesting and reinforces the need for careful interpretation of scans.

The study concluded that:

“The most incidental SSTR PET/CT findings were found in the thyroid gland, spine, and brain. The risk of malignancy was greatest in incidental SSTR PET/CT findings in the breast, cranially, and thyroid gland. The results of the present study can prove useful in the interpretation of atypical findings on SSTR PET/CT and in the counseling of clinicians.”

Using abstract data from the report, the incidental breast findings were associated with the highest risk of malignancy (67%). In the thyroid, incidental SSTR uptake was caused by malignancy in 8%, all presenting as focal uptake. The lowest risk was seen in the spine with a malignancy rate of 3% in patients with incidental SSTR uptake and benign cases were interpreted as vertebral hemangiomas on CT. Incidental SSTR PET/CT findings in other locations were of malignant etiology in two out of six cases (33%) and should be evaluated individually.  The study has details of the other locations. 

These findings in terms of locations correlate nicely with the seminal paper from Dr Michael Hofman which was covered in the pitfalls section of my general SSTR PET post linked below.  The other interesting study output is the malignancies discovered in the incidental finding indicate most incidental findings are benign in nature.  However, it also emphasises the importance of thorough checking when things are found incidentally via scans.  In fact, many people will have been diagnosed with NET via the same process!  

But something I emphasise in my ‘Understanding your SSTR PET Reports‘ blog post linked below, not everything that lights up on SSTR PET is NET and not everything that lights up on SSTR PET is a malignancy

Source Reference Citation

Prevalence and significance of incidental findings on 68 Ga-DOTA-conjugated somatostatin receptor-targeting peptide PET/CT: a systematic review of the literature – PMC (

Bentestuen M, Gossili F, Almasi CE, Zacho HD. Prevalence and significance of incidental findings on 68 Ga-DOTA-conjugated somatostatin receptor-targeting peptide PET/CT: a systematic review of the literature. Cancer Imaging. 2022 Sep 3;22(1):44. doi: 10.1186/s40644-022-00484-0. PMID: 36057635; PMCID: PMC9441055.

Understanding your SSTR PET Reports

Check out my article which is supplementary to my general SSTR PET blog post.

Click to read more

My general SSTR Blog post below

Click to read more

C-19 Pandemic

Click on the picture to read

After a few months of introducing C-19 vaccines, many cases of false-positive lymph nodes were reported on nuclear PET scans, some of which led to unnecessary biopsies and unnecessary worry for the patients concerned.

Read more about this phenomenon here or click on the picture:


I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me.  Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional as they are not members of the private group or followers of my sites in any official capacity.  Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 19,512 other subscribers.

Thanks for reading.


I’m also active on Facebook. Like my page for even more news. Help me build up my new site here – click here and ‘Like’

Sign up for my newsletters – Click Here


My Diagnosis and Treatment History

Follow me on twitter

Check out my online presentations

Check out my WEGO Health Awards

Like my new awareness page – click here or on the photo.  (Like rather than follow please!)

Check out my Glossary of Terms – click here

patients included

Please Share this post for Neuroendocrine Cancer awareness and to help another patient


Pancreatic NET with carcinoid syndrome – not as common as you think

Why do I need to write about this? I’ve been watching confusion surrounding symptomatic pancreatic NETs for years and it never ceases to amaze me

Read More »

A spotlight on Appendiceal Neuroendocrine Neoplasms

What are Appendiceal NENs Appendiceal Neuroendocrine Neoplams (NENs) account for approximately  60% of all primary cancers in the appendix.  The other main cancer types found

Read More »

Nuclidium wins award to study NET radiopharmaceutical – Phase 1 Clinical Trial of TraceNET (TM)

What is TraceNETTM TraceNETTM is a a novel copper-based ‘radiodiagnostic’ for detecting neuroendocrine tumours (NET). The PET imaging agent candidate is the diagnostic component of

Read More »

Experimental drug for Gastric NET – Netazepide

Gastric NETs When I wrote my post entitled “Spotlight on Gastric Neuroendocrine Neoplasms“, I explained what these were with some emphasis on the association with

Read More »

A Newsletter from RonnyAllan.NET – 13th March 2023

Newsletter from Ronny Allan – 13th March 2023 Welcome to my new template newsletter compiled using WordPress (my blog app). This is the 2nd in

Read More »

Fructose intolerance – the NET Effect

Background   When I cast my mind back to my very first surgery, I remember all sorts of ‘plumbing’ issues but was told it would take

Read More »

A tribute to the life and legacy of Miranda Filmer

It’s true to say that Neuroendocrine Cancer is an older person’s disease, the epidemiology is clear on that.  But I do see many young people

Read More »

Treatment for Neuroendocrine Cancer: Beware of the alternatives

The Alternative Hype Cancer Research UK warns of the risks in Alternative Therapies, and I pay great attention to what these guys say.  I know

Read More »

RonnyAllan.NET – Summary of February 2023 – Ronny Allan – Living with Neuroendocrine Cancer

Summary Another great start to 2023 and I thank those who continue to support my social media and this blog.  I’m keen to hear any

Read More »

I love comments - feel free!

%d bloggers like this: